1. X
  2. Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ
Log inSign up
Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ
6,473 posts
Image
user avatar
Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ
@APassaroMD
Med oncologist interested in lung cancer, biomarkers and drug development
Milan, Italy
ieo.it/en/PNA/doctorS…
Joined December 2016
224
Following
7,038
Followers
RepliesRepliesMediaMedia

New to X?

Sign up now to get your own personalized timeline!

Create account

By signing up, you agree to the Terms of Service and Privacy Policy, including Cookie Use.

Terms·Privacy·Cookies·Accessibility·Ads Info·© 2026 X Corp.
Don't miss what's happening
People on X are the first to know.
Log inSign up
  • Pinned
    user avatar
    Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ
    @APassaroMD
    Apr 18, 2020
    That you are here - that life exists and identity, That the powerful play goes on, and you may contribute a verse. Walt Whitman, Leaves of Grass (1892)
  • user avatar
    Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ
    @APassaroMD
    Oct 9, 2021
    🔥📡 kaboooom! Amazing news at @AACR #Targets21 🎯KRAS G12D is therapeutic TARGET! @Mirati presented the structure of MRTX1133, the reversible KRAS #G12D inhibitor. Great news for #LCSM, #Pancreatic Cancer #CRC, and more 🙌🙌🙌
    Image
  • user avatar
    Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ
    @APassaroMD
    Jan 20, 2022
    The light is On💡 Out our @NEJM editorial on Trastuzumab Deruxtecan in HER2-Mutant NSCLC by Bob Li et al. nejm.org/doi/full/10.10… #LCSM #LungCancer @peters_solange
    Image
  • user avatar
    Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ
    @APassaroMD
    Jan 23, 2023
    💡🔥Out today, the Oncogene-addicted metastatic NSCLC ESMO Guideline. A significant effort to improve the management of patients w/ #lungcancer harbouring 🔟 different gene alterations! This is an amazing manuscript & I am glad to be a part of it #LCSM sciencedirect.com/science/articl…
    Image
    31K031K
  • user avatar
    Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ
    @APassaroMD
    Feb 14, 2022
    🆕🌟I’m very proud to share our last manuscript titled “ESMO expert consensus statements on the management of EGFR mutant Non-Small Cell #LungCancer” #LCSM A global effort to improve the management of EGFR-positive disease Thanks to all the authors!!! annalsofoncology.org/article/S0923-…
    Image
  • user avatar
    Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ
    @APassaroMD
    Apr 15, 2021
    Happy to share our latest #review on overcoming therapy resistance in EGFR-mutant, just published with @NatureCancer 💡rdcu.be/ciK5E
    Image
  • user avatar
    Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ
    @APassaroMD
    May 29, 2020
    🔥🔥 Kaboooom! #ASCO20 #LCSM Finally a target agent for HER2-mutated NSCLC: Interim results of DESTINY-Lung01 (42 pts) mDOR: 7.75 mo ORR: 61.9% DCR: 90.5% Estimated mPFS = 14.0 mo 👉All pts (42/42) had TEAEs; 64.3% were grade ≥ 3 (52.4% drug-related)
    Image
  • user avatar
    Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ
    @APassaroMD
    Jun 3, 2022
    💥#ASCO22 #LCSM Concomitant publication @NEJM for the KRAYSTAL-1 ph2 trial, just presented by @AlexSpiraMDPhD Another step forward for the KRAS-g12C mutant NSCLC…& much more is coming! nejm.org/doi/full/10.10…
    Image
  • user avatar
    Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ
    @APassaroMD
    Jun 2, 2021
    #ASCO21 we are ready to go!💨 Here, some of the most interesting abstract on #LungCancer #LCSM that will be presented, very soon! Take a look at that & enjoy 👁‍🗨
    Image
  • user avatar
    Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ
    @APassaroMD
    Jan 17, 2023
    💥🔥just out in @Annals_Oncology, the NEW @myESMO guideline for non-oncogene addicted metastatic NSCLC #LCSM ‼️ Honoured to be part of this important document (waiting for oncogene addicted one), lead by @HendriksLizza & @MartinReck2
    Image
    Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for...
    From annalsofoncology.org
    31K031K
  • user avatar
    Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ
    @APassaroMD
    Sep 30, 2019
    #ESMO19 #LCSM Do you want to know how to treat patients with NSCLC and predictive biomarkers? Here, an excellent vademecum exploring available and upcoming target agents for #lungcancer by @dplanchard
    Image
  • user avatar
    Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ
    @APassaroMD
    Jun 20, 2022
    🧿Neoadjuvant Chemotherapy Plus Immuno in Early-Stage Resectable NSCLC #LCSM Happy to share our NADIM OGR companion article,just published in @JCO_ASCO focusing on endpoints,study design & challenges in the field of perioperative #immuno 📌Find it here ascopubs.org/doi/abs/10.120…
    Image
  • user avatar
    Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ
    @APassaroMD
    Sep 22, 2020
    👁‍🗨#ESMO20 the day after🔈 #LungCancer take-home 📬 ▪️KN024:31.9% 5yr-OS w/ 1L IO ▪️CROWN:PFS-HR Lorlatinib 0.28.🆕standard?Maybe no! ▪️LungART:PORT for pN2 cannot be reccomended as SoC ▪️ADAURA: towards approval ▪️Sotirasib for KRAS G12C ORR 32.3%/DoR 10.9m ▪️BLU-945:👈🏻😉 #LCSM
    Image
  • user avatar
    Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ
    @APassaroMD
    Mar 28, 2024
    🚀 Excited to announce our latest @CellCellPress publication on "Cancer biomarkers: Emerging trends and clinical implications for personalized treatment." An important collaboration shedding light on promising avenues in cancer research.📑✨ sciencedirect.com/science/articl…
    Image
    13K013K
Advertisement
Advertisement